News Read the latest news from Astellas Gene Therapies Dec 19, 2024 Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases Read More Oct 09, 2024 Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications Read More Nov 15, 2023 Astellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet Neurology Read More Jun 08, 2023 Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read More Feb 22, 2023 Astellas Announces Update on Preliminary Safety and Efficacy Data from FORTIS Study of Investigational AT845 in Adults with Late-Onset Pompe Disease Read More Jan 20, 2023 Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease Read More Jan 09, 2023 Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease Read More Oct 25, 2022 Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs Read More Jul 26, 2022 Astellas Unveils Plans to Open New Biotech Campus in South San Francisco Read More Pagination Current page 1 Page 2 Page 3 Next page Next › Last page Last »
